While pancreatic cancer is relatively rare in the U.S., a diagnosis can often mean a death sentence, with the National Cancer Institute pegging the 5-year survival rate at just over 7%. But researchers at the University of Texas Southwestern Medical Center may have found new possibilities for the treatment of pancreatic cancer, starting with CDK4/6 inhibitors.
Working with the knowledge that the CD44v6 protein acts as a co-receptor for receptor tyrosine kinases like MET and VEGFR-2 that drive pancreatic cancer, a group of German investigators say they've successfully tested a new peptide approach in mice that throws up a hurdle that can blunt and perhaps even stop the development of the disease.
Cardiovascular-focused Boston Scientific is moving deeper into oncology and expanding its vascular offerings with the purchase of the interventional radiology portfolio of CeloNova BioSciences. The deal with the San Antonio, TX-based startup involves a $70 million upfront payment with additional, undisclosed regulatory and sales milestones.
Researchers at Stanford University School of Medicine have found that combining two drugs that target the epigenome of cancer cells may be effective in killing off pancreatic tumor cells.
A two-drug combo that matches Afinitor with an experimental compound proved effective in killing pancreatic cancer cells and blunting tumor growth in cell lines and mouse models for the lethal disease.
OncoGenex, a small biotech going it alone in cancer R&D, said one of its drug prospects failed in a pancreatic cancer trial, denting the value of the company's pipeline.
Most cancer cells rely on glycolysis to provide energy for the cell, which doesn't use oxygen. Now scientists have discovered that pancreatic cancer stem cells, which they term PancSCs, mostly undergo oxidative phosphorylation, which not only requires oxygen but is a more efficient form of metabolism.
Research teams from the U.S. and Ireland are joining forces in the development of nanotechnology to treat pancreatic cancer. With a new grant of £2.9 million ($4.4 million), the international cohort aims to create chemotherapy-delivering treatments for the disease, which has the lowest 5-year survival rate of any common cancer.
Two researchers at the University of Houston say that recent work highlights the promise of liver X receptors, or LXRs, as a target for hard-to-treat cases of pancreatic cancer.
Promising research conducted by Dr. Ernest Wright and Dr. Jorge Barrio, both of UCLA's Jonsson Comprehensive Cancer Center, show two types of sodium-dependent glucose transports known as SGLT1 and SGLT2 are actively involved in glucose uptake into tumors. And that makes them prime targets for drug investigators.